By Chris Wack
Phio Pharmaceuticals shares were higher after the company reported positive pathology results for its Phase 1b Intasyl PH-762 trial.
The stock was 32% higher, at $2.72. Shares are up 55% year to date.
The biopharmaceutical company reported the pathologic results for three patients with cutaneous squamous cell carcinoma who completed treatment in the fifth and final dose cohort of the on-going Phase 1b dose escalation trial.
The company said there was 100% tumor clearance in one of patients, greater than 90% clearance in the second patient, and greater than 50% clearance in the third patient.
To date, a total of 18 patients with cutaneous carcinoma have completed treatment across five dose escalating cohorts in the Phase 1b trial. No patients in the study have exhibited clinical progression of disease. Phio may continue to screen and treat additional patients as part of the fifth cohort.
The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Phio also said that the Safety Monitoring Committee completed its pre-specified review of safety results for the first three patients in the fifth cohort and confirmed that there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects at this maximum dose concentration. There have been no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in any of the patients who have completed treatment with intratumoral PH-762 in this trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 03, 2025 13:33 ET (18:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.